Urotronic Inc. develops ground breaking drug/device combination technologies designed to benefit patients’ quality of life by addressing complex urologic conditions. The company’s first two products are focused on the treatment of urethral stricture disease and BPH. Optilume For Stricture was inspired by severe patient and physician dissatisfaction with current treatment options. Three year data for this revolutionary product demonstrates a greater than 75% rate of freedom from reintervention in patients with two or more prior endoscopic treatments. Optilume For Stricture just received its CE Mark and has completed enrollment of its pivotal US FDA Clinical Trial. The company’s second offering, Optilume BPH, is a promising new minimally invasive option for patients suffering with BPH. Patients are currently enrolling in its pivotal FDA Clinical Trial.
Please visit us at booth 210 or at www.urotronic.com for more information.
Brands: Optilume For Stricture and Optilume BPH